First NBD1 Stabilizer Enters Phase 2a Proof-of-Concept Readout

Sionna Therapeutics has completed enrollment in its PreciSION CF Phase 2a trial, positioning SION-719 as the first NBD1 stabilizer to reach clinical proof-of-concept evaluation in cystic fibrosis patients. For contract manufacturers and API suppliers tracking the post-Trikafta pipeline, the trial's summer 2026 topline readout will signal whether a new mechanistic class warrants serious capacity planning attention.

The randomized, double-blind, placebo-controlled, crossover study enrolled adult CF patients homozygous for the F508del mutation who are maintained on a stable, physician-prescribed dose of Trikafta (elexacaftor/tezacaftor/ivacaftor). SION-719 is being evaluated as an add-on to that standard of care, with primary objectives covering safety, tolerability, and pharmacokinetics, alongside sweat chloride as a pharmacodynamic endpoint reflecting CFTR function. The trial is registered as NCT07108153 and is being conducted across multiple sites, including those within the CF Foundation-supported Therapeutics Development Network, described as the largest CF clinical trials network in the world.

Mechanistic distinction matters here. Unlike existing CFTR modulators that act as potentiators or correctors at the protein surface, Sionna's approach targets nucleotide binding domain 1 directly, the region where the F508del mutation resides. The company's scientific rationale, built on more than a decade of co-founder research into NBD1 biology, holds that direct stabilization of this domain could deliver CFTR function improvements beyond what current triple-combination therapy achieves. Whether Phase 2a data support that hypothesis will determine how seriously the broader industry treats NBD1 stabilization as a viable development pathway.

Topline data from the PreciSION CF trial are anticipated in summer 2026, according to Sionna. Charlotte McKee, M.D., Chief Medical Officer, noted in the company's announcement that this represents the first clinical trial evaluating an NBD1 stabilizer in people with CF. Sionna Therapeutics is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, and is listed on Nasdaq under the ticker SION.